Vesatolimod
- Generic Name
- Vesatolimod
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H30N6O2
- CAS Number
- 1228585-88-3
- Unique Ingredient Identifier
- O8M467C50G
- Background
Vesatolimod has been used in trials studying the treatment of Hepatitis B and Chronic Hepatitis B.
- Associated Conditions
- -
- Associated Therapies
- -
Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels
- Conditions
- Interventions
- First Posted Date
- 2022-07-14
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 18
- Registration Number
- NCT05458102
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, LLC., Miami, Florida, United States
🇺🇸Collaborative Neuroscience Research, LLC., Long Beach, California, United States
🇺🇸Triple O Research Institute, P.A., West Palm Beach, Florida, United States
Study of VRC07-523LS, CAP256V2LS, and Vesatolimod, in Early Antiretroviral-treated HIV-1 Clade C-infected Women
- Conditions
- Interventions
- First Posted Date
- 2022-03-16
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 21
- Registration Number
- NCT05281510
- Locations
- 🇿🇦
FRESH Clinical Research Site: Females Rising through Education, Support and Health, Umlazi, South Africa
Study to Evaluate the Safety and Efficacy of Vesatolimod in Antiretroviral Treated Human Immunodeficiency Virus (HIV-1) Infected Controllers
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2021-04-21
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 25
- Registration Number
- NCT03060447
- Locations
- 🇺🇸
Peter Shalit, MD, Seattle, Washington, United States
🇺🇸Central Texas Clinical Research, Austin, Texas, United States
🇺🇸Zuckerberg San Francisco General, San Francisco, California, United States
Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults
- Conditions
- Interventions
- First Posted Date
- 2016-08-08
- Last Posted Date
- 2020-02-21
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 48
- Registration Number
- NCT02858401
- Locations
- 🇺🇸
Midway Immunology & Research Center, Fort Pierce, Florida, United States
🇺🇸University of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸Mills Clinical Research, Los Angeles, California, United States
Study to Evaluate the Safety, Tolerability, and Efficacy of Vesatolimod in Combination With Tenofovir Disoproxil Fumarate (TDF) in Adults With Chronic Hepatitis B (CHB) Infection Who Are Currently Not Being Treated
- First Posted Date
- 2015-10-19
- Last Posted Date
- 2020-05-18
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 192
- Registration Number
- NCT02579382
Study To Evaluate Safety and Efficacy of Vesatolimod for the Treatment of Chronic Hepatitis B Virus in Virally-Suppressed Participants
- First Posted Date
- 2014-06-18
- Last Posted Date
- 2020-10-14
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 162
- Registration Number
- NCT02166047
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.